Share this article:
CEO, UROVANT SCIENCES LTD.
WHY: Healthcare exec with specialty in urology. Taking over Irvine-based company as its principal medication that treats overactive bladder issues, vibegron, gets close to FDA approval and domestic sales can begin.
NOTABLE: Oversaw the commercial launches of two of the most successful overactive bladder therapies in the U.S. as president of Americas Operations at Japanese giant Astellas Pharma Inc., where his unit generated $4B in annual revenue.